Access 470,000 products and nearly 40,000 drug profiles to analyze successful launch strategies and be ready for what’s next.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSA rare disease is defined as a condition that affects less than 200,000 people in the USA and fewer than 1 in 2,000 people in the EU. The development of orphan drugs was previously rare due to the small size of patient populations, which acted as a barrier for commercial development in the research and development of rare diseases. Regulatory bodies in major markets have introduced new legislation with the aim of providing incentives for the development of medicines for rare diseases, including the US FDA's Orphan Drug Act in 1983, followed by Japan in 1993 and the EU in 2000. These incentives, including extended market exclusivity (7 years in USA and 10 years in EU), and the advancement in new technologies have driven the growth in ground-breaking research against rare diseases and the development of orphan drugs.
The Orphan Drug Act has resulted in a greater number of orphan drugs approved in the USA since its enactment, driven by the approval of rare oncology products and secondary indications. As of March 2023, there have been 6,506 orphan drug designations granted by the US FDA of which 1,144 have led to orphan-designated approval from the agency. This review provides an insight into key selected significant therapeutic developments in rare diseases with data sourced from IQVIA Pipeline Link, a proprietary drug pipeline database.
Rare disease drug development has recently focused on hematology, neurology, infectious disease, metabolism/endocrinology, rheumatology/immunology, cardiovascular, gastroenterology, pulmonary and ophthalmology therapeutic categories. There are currently several key orphan drugs in development that may emerge as the next rare disease therapies.
To read more, please fill in your details on the left to download the article.
Access 470,000 products and nearly 40,000 drug profiles to analyze successful launch strategies and be ready for what’s next.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.